QP-Brain®
AI-based software for brain volumetry and white matter hyperintensity analysis
Software · Cloud SaaSCompany source
Company profile
About QUIBIM S.L.
Quibim S.L. is a medical imaging AI company that develops pioneering radiomics technology and software-as-a-medical-device solutions to unlock insights from imaging data and improve patient outcomes. The company has built a comprehensive cloud-based, tissue-agnostic platform that extracts key radiomics drivers from large-scale imaging data registries, enabling precision medicine applications across oncology, neurology, and other therapeutic areas. Quibim's product portfolio includes regulatory-cleared medical devices for clinical use: QP-Prostate for automated prostate MRI analysis with PI-RADS compliance, QP-Brain for brain volumetry and white matter hyperintensity analysis, QP-Liver for quantifying hepatic fat and iron concentration, and QP-Insights for comprehensive multi-omics data management and radiomics research. These solutions integrate seamlessly with existing PACS systems through QP-Link, providing automated workflows that deliver quantitative, standardized reports directly to clinical systems. The company serves three primary markets: healthcare providers seeking to enhance diagnostic accuracy and workflow efficiency, biopharma companies accelerating drug development programs through imaging biomarkers, and research institutions conducting clinical studies. Quibim's platform manages over 100,000 de-identified cancer patient records and millions of research imaging datasets, with deployment across multiple international sites. The technology emphasizes data security with ISO 27001:2022 certification, HIPAA and GDPR compliance, and encryption at rest and in transit on Microsoft Azure's cloud infrastructure. Quibim partners with leading healthcare institutions and pharmaceutical companies to extract real-world evidence and develop prognostic and predictive models. The company's radiomics approach provides detailed quantitative insights beyond traditional imaging methods, supporting personalized treatment planning, patient stratification for clinical trials, and monitoring of treatment response and adverse events.
Company description QUIBIM S.L. official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Work at QUIBIM S.L.?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- B-Cell lymphoma
- Brain atrophy
- Breast cancer
- Diffuse large B cell lymphoma
- Iron overload
- Liver steatosis
- Lung conditions
- Neuroblastoma
- Neurological diseases
- Prostate cancer
- White matter hyperintensities
Who it serves
- Biopharma companies
- Healthcare providers
- Hospitals
- Real-world evidence specialists
- Research institutions
Deployment & integration
Cloud Saas · Hybrid deployment with recorded integration context.
Recorded integration context: DICOM Web tools, EHR data, PACS systems, QP-Link bridge software for local PACS connectivity.
Geographic context
MarketsCanada (Health Canada licence received) · Germany · Global deployment · Spain · United States (New York AI program)
Company sourceOfficial website
Company milestones
Platform expansion
QP-Prostate received Health Canada licence (June 2026), selected for New York strategic AI program (May 2026), partnership with Vara to bring breast cancer screening AI to Spain (April 2026)
Partnerships
Recorded partners
- Healthcare institutions globally
- Top-tier biopharma companies (unnamed)
- Vara (Germany) for breast cancer screening AI in Spain
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
QP-Breast®
AI solution for breast cancer screening and analysis
Software · Cloud SaaSCompany source
QP-Insights®
Cloud platform for managing and analyzing large-scale multi-omics data and medical images
Platform · Cloud SaaSCompany source
QP-Link®
Secure bridge between local PACS and Quibim Cloud for automated workflow
Software · HybridCompany source
QP-Liver®
Post-processing solution for liver fat and iron quantification with automated segmentation
Software · Cloud SaaSCompany source
QP-Lung®
AI solution for lung imaging analysis
Software · Cloud SaaSCompany source
QP-Prostate®
AI solution for prostate MRI analysis with automated segmentation and lesion detection
Software · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
No linked records are currently available.
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
QP-Prostate® CADK242683 · 510k · Mar 18, 2025
QP-Brain®K232231 · 510k · Dec 13, 2023
QUIBIM Precision Prostate (qp-Prostate)K203582 · 510k · Feb 4, 2021
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Improved diagnostic accuracy
Through automated quantitative analysis and standardized reporting
Workflow efficiency
Automated segmentation reducing manual clinician time
Standardized decision-making
PI-RADS compliant prostate MRI analysis
Patient stratification
Identifying candidates for clinical trials and predicting drug response
Vara partnership (Germany to Spain)
Bringing Europe's leading breast-cancer screening AI to Spain
Partnership established to expand breast cancer screening capabilities
B-Cell lymphoma CAR-T therapy study
Predicting survival, neurotoxicity, and response in B-Cell lymphoma patients treated with CAR-T therapy
Developed imaging features-based model for predicting patient outcomes
Neuroblastoma risk stratification study
Empowering neuroblastoma risk stratification through AI algorithms
Enhanced risk stratification capabilities using AI
Diffuse large B cell lymphoma study
Prognostic value assessment of genetic alterations and 18F-FDG PET/CT imaging features
Established prognostic value of imaging features in lymphoma
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from QUIBIM S.L.
Recent articles published on QUIBIM S.L.'s official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.